Mandorfer, Mattias http://orcid.org/0000-0003-2330-0017
Aigner, Elmar
Cejna, Manfred
Ferlitsch, Arnulf
Datz, Christian
Gräter, Tilmann
Graziadei, Ivo
Gschwantler, Michael
Hametner-Schreil, Stephanie
Hofer, Harald
Jachs, Mathias
Loizides, Alexander
Maieron, Andreas
Peck-Radosavljevic, Markus
Rainer, Florian
Scheiner, Bernhard
Semmler, Georg
Reider, Lukas
Reiter, Silvia
Schoder, Maria
Schöfl, Rainer
Schwabl, Philipp
Stadlbauer, Vanessa
Stauber, Rudolf
Tatscher, Elisabeth
Trauner, Michael
Ziachehabi, Alexander
Zoller, Heinz
Fickert, Peter
Reiberger, Thomas
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 28 April 2023
Accepted: 15 May 2023
First Online: 26 June 2023
Conflict of interest
: M. Mandorfer served as a speaker and/or consultant and/or advisory board member for AbbVie, Albireo, Collective Acumen, Gilead, Takeda, and W. L. Gore & Associates and received travel support from AbbVie and Gilead. E. Aigner served as a speaker and/or consultant and/or advisory board member for Gilead, Sanofi-Genzyme, Takeda, Advanz Pharma, Roche, Novartis. B. Scheiner received travel support fromm AbbVie, Ipsen and Gilead. M. Gschwantler received grants from AbbVie, Gilead, and MSD; speaking honoraria/advisory board fees from AbbVie, Gilead, MSD, Janssen, BMS, Roche, Intercept, Alnylam, Norgine, AstraZeneca, Falk, Gebro Pharma and Shionogi. M. Jachs served as a speaker and/or consultant for Gilead and received travel support from Gilead. S. Hametner-Schreil served as speaker and/or advisory board member for AbbVie, Gilead, Roche and MSD. M. Peck-Radosavljevic has served as an investigator for AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Exelixis, Eisai, Gilead, Lilly, Ipsen, Novartis, and Roche. He has served as speaker or adviser for AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Eisai, Gilead, Ipsen, Lilly, MSD, and Roche. He received grant support from Bayer and Gilead, and he served in data and safety monitoring boards for BMS, Boehringer Ingelheim, Lilly-Imclonse and ONEXO. P. Schwabl served as constultant for PharmaIN. R. Stauber served as a speaker for Boston Scientific and Medtronic. S. Reiter received speakers’ honoraria from Intercept Pharma Austria as well as travel support from AbbVie and Gilead. M. Trauner received grant support from Albireo, Alnylam, Cymabay, Falk, Gilead, Intercept, MSD, Takeda, and UltraGenyx, honoraria for consulting from Albireo, Boehringer Ingelheim, BiomX, Falk, Genfit, Gilead, Hightide, Intercept, Janssen, MSD, Novartis, Phenex, Pliant, Regulus, and Shire, speaker fees from Bristol-Myers Squibb, Falk, Gilead, Intercept, and MSD, as well as travel support from AbbVie, Falk, Gilead, Intercept and Jannsen. V. Stadlbauer received speaker’s honoraria and travel support from Merz Therapeutics, Albireo, Sanofi. T. Reiberger served as a speaker and/or consultant and/or advisory board member speaking honoraria from AbbVie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Roche, Siemens, and W. L. Gore & Associates and received travel support from AbbVie, Boehringer-Ingelheim, Gilead, and Roche as well as grants/research support from AbbVie, Boehringer-Ingelheim, Gilead, Intercept, MSD, Myr Pharmaceuticals, Philips Healthcare, Pliant, Siemens, and W. L. Gore & Associates. M. Cejna, A. Ferlitsch, C. Datz, T. Gräter, I. Graziadei, H. Hofer, A. Loizides, A. Maieron, F. Rainer, , G. Semmler, L. Reider, M. Schoder, R. Schöfl, E. Tatscher, A. Ziachehabi, H. Zoller and P. Fickert declare that they have no competing interests.